$252 Million is the total value of CHI Advisors LLC's 28 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PLRX | Sell | PLIANT THERAPEUTICS INC | $52,266,211 | -7.5% | 3,014,199 | -3.3% | 20.72% | +20.9% |
| RPTX | Sell | REPARE THERAPEUTICS INC | $35,837,422 | +13.0% | 2,966,674 | -1.1% | 14.20% | +47.5% |
| Sell | ACELYRIN INC | $23,014,608 | -58.7% | 2,262,990 | -15.0% | 9.12% | -46.0% | |
| LABD | Sell | DIREXION SHS ETF TRdaily s&p biotec | $4,635,000 | -0.8% | 225,000 | -30.8% | 1.84% | +29.6% |
| BDTX | Sell | BLACK DIAMOND THERAPEUTICS I | $2,066,400 | -45.4% | 720,000 | -4.0% | 0.82% | -28.7% |
| Sell | RALLYBIO CORP | $1,316,774 | -57.1% | 390,734 | -28.0% | 0.52% | -44.0% | |
| Sell | DISC MEDICINE INC | $1,174,500 | -78.9% | 25,000 | -80.0% | 0.47% | -72.4% | |
| DTIL | Sell | PRECISION BIOSCIENCES INC | $207,043 | -75.5% | 606,629 | -62.2% | 0.08% | -68.0% |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -0.14% | – |
| HOOK | Exit | HOOKIPA PHARMA INC | $0 | – | -788,740 | -100.0% | -0.21% | – |
| VECT | Exit | VECTIVBIO HLDG AG | $0 | – | -2,782,756 | -100.0% | -14.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.